Although each tested AML cell line harbored various types of genetic abnormalities such as MLL-AF9 or FLT3-ITD translocation, TAS4464 treatments decreased cell viability, which was accompanied by cell death in all evaluated AML cell lines (Fig. 1A). This evidence concerns the gene KMT2A and acute myeloid leukemia.